Trisomy 21 as a Risk Factor for Severe Illness in COVID-19: Report of two Cases.

COVID-19 Down syndrome Risk factors Trisomy, Risk factor

Journal

Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 7 5 2021
pubmed: 8 5 2021
medline: 8 5 2021
Statut: ppublish

Résumé

COVID-19 leads to mild symptoms within the majority of infected patients, but can cause severe multiple organ failure and death. There is only limited information regarding the consequences of this new emerging infection with congenital disorders. According to the previous studies, many people with Down syndrome are considered high risk for complications related to respiratory diseases. We report two trisomy 21 patients who suffered from COVID-19 and summarize the early experience with COVID-19 and Down syndrome. The course of the disease was severe in these two cases, and our concern is close monitoring of the patients with Down syndrome for early signs of COVID-19.

Identifiants

PMID: 33959180 PMC: PMC8088146
pubmed: 33959180
pii: Tanaffos-19-413
pmc: PMC8088146

Types de publication

Case Reports

Langues

eng

Pagination

413-417

Informations de copyright

Copyright© 2020 National Research Institute of Tuberculosis and Lung Disease.

Références

J Pediatr. 2011 Feb;158(2):319-25
pubmed: 20846671
Emerg Infect Dis. 2010 Aug;16(8):1312-4
pubmed: 20678334
Pediatrics. 2018 Sep;142(3):
pubmed: 30093540
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
J Caring Sci. 2012 Aug 25;1(3):145-51
pubmed: 25276689
Cell Rep Med. 2020 May 19;1(2):100019
pubmed: 32501455
Am J Med Genet A. 2019 Feb;179(2):161-176
pubmed: 30582784
J Cell Physiol. 2021 Apr;236(4):2430-2442
pubmed: 32901940
BMJ. 2014 Sep 30;349:g5596
pubmed: 25269800
Pediatrics. 2009 Dec;124(6):1565-71
pubmed: 19948627
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24231-24241
pubmed: 31699819
J Clin Immunol. 2020 Oct;40(7):974-976
pubmed: 32648027
Tanaffos. 2020 Nov;19(2):91-99
pubmed: 33262795
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Eur Respir Rev. 2017 Feb 21;26(143):
pubmed: 28223397
Int J Cardiol. 2020 Jun 15;309:70-77
pubmed: 32248966
Tanaffos. 2020 Nov;19(2):108-111
pubmed: 33262797

Auteurs

Abdolreza Babamahmoodi (A)

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Afshin Moniri (A)

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Makan Sadr (M)

Virology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Seyed Mohammad Poorhosseini (SM)

Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

Mitra Rezaei (M)

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Virology Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Majid Marjani (M)

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Ali Akbar Velayati (AA)

Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Classifications MeSH